Evaluating Deucravacitinib for Pediatric Plaque Psoriasis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the drug levels, efficacy, and safety of Deucravacitinib in children and adolescents aged 4 to less than 18 years with moderate to severe plaque psoriasis. The study is divided into two cohorts based on age, with Part A focusing on determining appropriate dosing and Part B evaluating the treatment's effectiveness and safety. Participants who complete the initial phases will have the opportunity to enter a long-term extension period to monitor ongoing safety and tolerability.

Why it matters

Who can join: the full rules

Inclusion Criteria

* Males and females aged 12 to \<18 years for Cohort 1. Males and females aged 4 to \<12 years for Cohort 2.
* Plaque psoriasis for at least 6 months.
* Moderate to severe disease.
* Candidate for phototherapy or systemic therapy.
* Must have completed the Week 52 treatment period in Part A or B for long-term extension (LTE) period.

Exclusion Criteria

* Participants weighing ≤ 30.0 kg at screening for Cohort 1 (age 12 to \< 18 years), Part A and Part B. Participants weighing \< 18.0 kg at screening for Cohort 2 (age 4 to \< 12 years), Part A and Part B.
* Other forms of psoriasis.
* History of recent infection.
* Prior exposure to deucravacitinib (BMS-986165) or another active comparator.
* Evidence of active TB for LTE period.
* Other protocol-defined inclusion/exclusion criteria apply.

Where it's running

• Instituto de Neumonologia Y Dermatologia
  Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina Recruiting
• Psoriahue
  Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina Recruiting
• CONEXA Investigacion Clinica S.A.
  Buenos Aires, Argentina Recruiting
• Centro de Investigaciones Metabólicas (CINME)
  Buenos Aires, Argentina Recruiting
• Hospital Italiano de Buenos Aires
  Caba, Argentina Recruiting
• Consultora Integral de Salud
  Córdoba, Argentina Recruiting

+15 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
• Email: Clinical.Trials@bms.com
• Phone: 855-907-3286

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term safety of deucravacitinib versus ustekinumab for plaque psoriasis (PRAGMATYK)

  This study will test whether deucravacitinib or ustekinumab has better long-term safety for adults with moderate-to-severe plaque psoriasis who have cardiovascular risk factors.

  Recruiting at 323 sites Phase 3 Bristol-Myers Squibb · Birmingham, Alabama and 410 other locations · NCT07116967

• Deucravacitinib for teens with moderate to severe plaque psoriasis

  This trial will test whether deucravacitinib helps teens with moderate to severe plaque psoriasis while tracking safety and drug levels.

  Recruiting at 89 sites Phase 3 Bristol-Myers Squibb · Birmingham, Alabama and 132 other locations · NCT06979453

• Comparing the effectiveness of deucravacitinib and apremilast for plaque psoriasis in adults in Japan

  This study is testing whether a new medication called deucravacitinib works better than apremilast for adults with plaque psoriasis in Japan.

  Recruiting at 2 sites Bristol-Myers Squibb · Minato-ku, Tokyo and 1 other locations · NCT06382987

• How safe and well ZP9830 works in people with plaque psoriasis over 8 weeks

  This study tests whether ZP9830 is safe and tolerable in adults with plaque psoriasis for 8 weeks, with a comparison to placebo.

  Recruiting Phase 1 Zealand Pharma · Leiden, South Holland · NCT07733089

• Secukinumab retention in adults with plaque psoriasis and MASLD in Spain

  This study tests how long people with plaque psoriasis and MASLD stay on secukinumab in real-world Spain, using EMR data from several hospitals.

  Recruiting at 9 sites Novartis · Badalona, Barcelona and 8 other locations · NCT07683065

• Deucravacitinib for scarring hair loss (frontal fibrosing and central centrifugal alopecia)

  This trial will test whether taking deucravacitinib once daily for 48 weeks helps adults with frontal fibrosing alopecia or central centrifugal cicatricial alopecia.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07508488

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.